Curriculum Vitae

PERSONAL INFORMATION

Family name, First name: Bostyn, Sven
Nationality: Belgium

Address:
Doris Lessings Vej 41B
DK – 2300 Copenhagen S
Denmark
Tel: +45 61 61 04 71

- **EDUCATION**

1997 – 2001 PhD, University of Maastricht Law Faculty, The Netherlands, Supervisors: Prof. Dr. Harm-Jan De Kluiver and Prof. Dr. Jan Brinkhof;

1993 – 1995 Advanced Master of Laws (LL.M.), University of Stockholm. Graduated 'summa cum laude' with thesis: "Patent law and biotechnology: current issues and future perspectives. An analysis of legal and ethical aspects related to patenting biotechnology."

1985 – 1991 Master of Laws (Lic.Jur.), specialisation labour and social security law (cum laude), at the University of Gent (UGENT)

- **LANGUAGE SKILLS**

	Read	Write	Speak
Dutch	Native language		
French	Excellent	Excellent	Excellent
English	Excellent	Excellent	Excellent
German	Excellent	Fairly good	Good
Swedish	Good	____	____
Norwegian Danish	Good	-------	------
Italian	Fairly good		Fairly good
Spanish	Basic notions		

- **CURRENT POSITION(S)**

2018 – Associate Professor of Biomedical Innovation Law, Faculty of Law, University of Copenhagen;
2018 - CEO and Managing Director of Bostyn IP and Photography Consulting ApS;
2014 - Lecturer CEIPI courses, Strasbourg;
2004 – Assistant Professor in Intellectual Property law, Institute for Information Law (IVIR), University of Amsterdam, Faculty of Law (fractional appointment)

- **PREVIOUS POSITIONS**

2010 – 2018 Senior Lecturer in law, University of Liverpool, School of law, Faculty of Humanities and Social Sciences, UK;
2010 – 2018 CEO and Managing Director of Expert IP Advice Ltd;
2010 – 2017 Chargé de cours invité (Visiting Professor), Université de Liège, Belgium ;
2004 – 2010 Senior Legal Counsel, De Clercq & Partners Patent Attorneys, Belgium;
1996 – 2003 Assistant Professor in commercial and intellectual property law at Maastricht University, The Netherlands;
1992 – 1993 Responsible for reorganisation of a department within Volvo Truck Parts Gent

- **FELLOWSHIPS AND ADVISORY POSITIONS**

2020 - Acting Professorial Lecturer at the WIPO Intellectual Property Law Course in Torino, where I am teaching pharmaceutical and biotechnological inventions, plant patents, plant variety rights;
2018 - Member of the steering committee for the Max Planck research project "Rechtsschutz biologischer Innovationen und Erfindungen" (MPI), 2018-2020;
2018 External ad-hoc member of the Meeting of the European Commission Expert Group on Industrial Policy in the presence of outside experts to discuss the application of the Biotech Directive in the field of plants, Brussels, 5 November 2018.
2006-2016 Lecturer Dutch Patent Attorney Qualifying Training (Opleiding Nederlandse Octrooigemachtigden) (2006-2016);
2001-2010 Acting Professorial Lecturer at the WIPO Intellectual Property Law Course in Torino (2001-2010), where I was teaching biotechnological inventions, plant patents, plant variety rights and university inventions;
1998 Appointed as national rapporteur for the Kingdom of the Netherlands for the XVth International Congress of Comparative Law 1998 in connection with the subject “The legal protection of biological elements” (general rapporteur, Prof. Dr. Dr. h.c. J. Straus, Max-Planck-Institut für Immaterialgüter- und Wettbewerbsrecht, München);
1997-1999 Visiting Research Fellow at the Max-Planck-Institut für Immaterialgüter- und Wettbewerbsrecht, München, (1997 and 1999);
1994 – 1995 Guest Research Fellow in patent law at the University of Stockholm, Faculty of Law.

- **PROFESSIONAL EXPERIENCE – NON-ACADEMIC**

In private practice from 2004-2010, and as from 2010 until present active as legal consultant. Advising clients on all matters relating to intellectual property law, contract law and licensing contracts.

Drafting court briefs on behalf of clients, acting as expert witness in court proceedings, drafting advice to clients, assisting clients in negotiations re IP matters, from enforcement over infringement to licensing in or out of IP rights. Advising clients on freedom to operate.

Providing strategic advice to clients regarding both IP portfolio as IP portfolio management.

Specialised in pharmaceuticals, biotechnology, including plant related IP, software and medical devices.

Advising clients on regulatory matters, specifically in the areas of pharmaceuticals, biotechnology and

medical devices.

Advising clients on competition law matters in the context of IP protection and related.

Advising clients on SPC filing, SPC strategy and conducting oral proceedings before national patent offices regarding SPC's or SPC applications.

Negotiating and drafting a range of contracts, in particular service level agreements, NDA's, cooperation agreements, licensing agreements etc.

Drafting and submitting amicus curiae briefs to the EBA on behalf of clients or in own capacity

Acting as expert witness in court proceedings (e.g., Monsanto case (which eventually led to an ECJ judgement)).

Policy work in a variety of Working Groups, such as EuropaBio, the European Commission, contacts with national and European members of (European) Parliament etc.

Clients ranging from SME's to multinational (listed) companies.

I have been involved in a wide variety of patent law cases, and have had the fortune of being involved in some landmark cases such as e.g., the CJEU Monsanto and Neurim cases.

- **EXPERT ACTIVITIES**

2020 -	Reviewer of research funding applications in social sciences for several national research councils, amongst which the Dutch NWO;
2018 -	Member of the steering committee for the Max Planck research project "Rechtsschutz biologischer Innovationen und Erfindungen" (MPI), 2018-2020;
2018-2019	Expert partner and co-author in EU commissioned study: "Study on a collaboration system for commercialisation of intellectual property in the EU, 29 July 2019, 101 pp.;
2017-2018	Expert partner and co-author in Project relating to evaluation of SPC protection and regulatory exclusivities in the Netherlands and Europe (Dutch Ministry of Health and Ministry of Economic Affairs and Climate) (2017-18);
2017-2018	Expert partner and co-author in Project relating to the evaluation of innovation policies in the Netherlands (Ministry of Economic Affairs and Climate) (2017-18);
2013-2016	Chair of the Expert Committee at the European Commission on the development and implications of patent law in the field of biotechnology and genetic engineering (2013-2016);
2003-2012	Member of the Expert Committee at the European Commission (DG Internal Market and DG Research) for the evaluation of Directive 98/44/EC relating to the legal protection of biotechnological inventions; Rapporteur for the subject 'Patenting DNA Sequences and Scope of Protection' (2003-2012);
2007-2008	Member Ad hoc expert Committee on patent law at the Belgian Royal Academy of Sciences (2007-2008);
2006-2007	Expert member EC sponsored research project "Transposition directive 98/44/EC in the new member states" (2006-2007);
2002-2006	Chairman of IPR Working Group in an EU funded international research project on cancer (TRANSBIG) (2002-2006);
2002-2006	Member of the Ethics and Legal Affairs Committee in an EU funded international research project on cancer (TRANSBIG) (2002-2006);
2004-2005	Ad hoc expert in Committee on Globalisation and Committee for Economic Affairs, Federal Parliament (Belgium) regarding patent law (2004-2005);
2003	Collaborateur Human Gene Project, Université de Montréal (2003);
2002-2003	Member of a Scientific Advisory Committee at the Netherlands Royal Academy of Arts and Sciences (Gene Patents Committee), as the patent law expert (investigating the effects of human gene patents on health care, innovation and scientific research) (2002-2003);
1998-1999	Ad Hoc external expert at the Discussion Forum on Medical Biotechnology (Platform Medische Biotechnologie, Ministry of Health and Parliament (1998-1999);
1999-2003	Legal advisor of Maastricht University in matters relating to patents and licensing policy

(until 2003);

1999-2002 Co-founder of Maastricht University Technology Transfer and Chair of the Maastricht University Technology Transfer Fund (until 2002);

1998-1999 Member expert committee Dutch Ministry of Health (Health and Care Council);

- **SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS**

Having supervised and/or supervising and/or externally examining the following PhD candidates:

2019 - Supervisor of a PhD student in Copenhagen in the area of antimicrobial resistance;

2018 - Supervisor of a Postdoctoral researcher in the area of orphan drugs:

2018 - Supervisor of a Postdoctoral researcher in the area of new uses of existing pharmaceutical products

2017 External Examiner for PhD relating to trade marks at University of Bolton in 2017;

2016 External examiner for PhD relating to SPC's at Trinity College Dublin in 2016;

2013-2019 Bianca Hanuz (Liverpool): Examining the application of blockchain technology as a solution to and the enabler of end-user online copyright infringement (2019) (supervisor);

2012-2015 Lodewijk Pessers (UVA, IViR, Amsterdam): Parameters and effectiveness of the inventive step requirement in patent law (successfully defended December 2015) (supervisor);

2010-2014 Natalia Kapetanaki (ULB, Brussels, member of the « Comité d'accompagnement »): Refus d'accorder une licence relative à un brevet sur une séquence d'ADN : légitime exercice d'un droit exclusif ou abus de position dominante? (successfully defended February 2014) (co-supervisor);

1996-2020 Supervisor of numerous bachelor and master theses (around 150)

- **TEACHING ACTIVITIES**

2018 - Teaching activities at the University of Copenhagen, Denmark:
Couse director of the following undergraduate modules:
1. Intellectual property rights in the digital age (15 ECTS)

(Co-)course director of the following postgraduate modules:
1. Life Sciences Law (15 ECTS)
2. European Intellectual Property Law (15 ECTS)
3. Technical Innovation, Market Power and Fairness in Society (15 ECTS)

Teaching in all of the aforementioned courses

I have also developed two Summer School courses, one in IP in Life Sciences and one in Regulatory Issues in Life Sciences, aimed at practitioners, in-house counsel, judges, civil servants etc

2004 - Teaching activities at the University of Amsterdam, Institute for Information Law, The Netherlands:
Course director Patent Law (Master level, 6 ECTS; selective course, entry requirements. Elective course within the Master in Information Law, total of 50 students allowed in the programme. Between 25 and 50 students)
Teaching in the said course

2010-2018 Teaching activities at the University of Liverpool, UK:

All courses taught annually since 2010.

Course director of the following undergraduate Bachelor modules (all 15 ECTS):

1. Intellectual Property Law I (copyright, design and enforcement of IP rights; student numbers went from 80 in 2010 to 210 in 2018);
2. Intellectual Property Law II (trade marks, passing off and patents; student numbers went from 80 in 2010 to 210 in 2018):
3. Patents, Right to Health and Access to Affordable Medicines (limited to max. 50 students).

Course director of the following postgraduate Master modules (all 20 ECTS):

1. Intellectual property in a global economy (focussing on globalisation issues and intellectual property law, with particular emphasis on international treaties and TRIPs; student numbers between 25 and 50);
2. Patents, Competition and Technological Development (covering the relationship between innovation, intellectual property law, and competition law; student numbers between 10 and 20).

Teaching in all of the aforementioned courses

1996-2003 Teaching activities at the University of Maastricht, The Netherlands:

(All courses apart from the Willem Vis Moot Court were taught annually between 1996-2003:

Maastricht uses exclusively problem-based learning, i.e., a student-centred pedagogy in which students learn about a subject through the experience of solving an open-ended problem found in trigger material. The PBL process does not focus on problem solving with a defined solution, but it allows for the development of other desirable skills and attributes (definition taken from Wikipedia.) Such system works with small class sizes of maximum 15 students. For courses which attract more students, multiple classes are organised which can be covered by multiple lecturers.

+ Course director of the following courses:

1. Dutch and International Commercial Law for Dutch law students (covering subjects such as international commercial contracts, international sale of goods, law of transportations; bills of exchange, private international law related to international contracts, Incoterms etc) (Master level, 6 ECTS, from 1996-2003; student numbers went from 40 in 1996 to 80 in 2003);
2. International Contract Practice (for European Law School students, a practice oriented course, covering a number of varying subjects such as international commercial contracts, licensing agreements etc, where students get to work on cases presented to them by companies and/or law firms and have to present orally solutions found) (Master level 6 ECTS; selective course with entry requirements, max 25 students allowed.);
3. European and International Commercial Law (for post-graduate Master students, i.e., students which already have obtained a Master in Laws degree, and study a further post-graduate Master degree, 6 ECTS; 15 students);
4. Coordinator of the Willem Vis Moot Court International Commercial Arbitration competition (we participated for the first time in 2000-2001, and won the Pieter Sanders Award for Memorandum of Claimant and an Honourable Mention for Memorandum of Respondent) (Master level, 6 ECTS; one team of 5 students).

+ Co-course director for the following courses:

5. Intellectual Property Law (for Dutch law, European Law School and post-graduate students) (Master level, 6 ECTS, between 30 and 50 students);
6. International Business Law for Business Students (Bachelor level, 8 ECTS, between 200 and 300 students, depending on the year).

Teaching in all of the aforementioned courses

- **INSTITUTIONAL RESPONSIBILITIES**

2018 – Copenhagen:

- Coordinating three major externally funded research projects: Co-PI of a project relating to orphan drugs, and coordinator for one relating to antimicrobial resistance, and another relating to new uses for existing pharmaceutical products (about 1 million EUR per project);
- Chair of various assessment committees for recruiting PhD students and Postdocs. Member of selection and interview committees for the same.

2010 - 2018 Liverpool

- Director for Liverpool On-Line Studies (2017-2018), having within my remit quality overview of teaching delivery and assessment, Chair of Board of Examiners, Chair of Board of Studies, Chair of Extenuating Circumstances Committee, Chair of Academic Integrity Committee, Member of Operations Management Group Liverpool On-Line Studies, auditing admission of students for LLM programmes, strategic overview of module and programme development and approval.
- Director of European and International Partnerships (2014-2016): having within my remit development of a network of European and international partners and international recruitment of students, besides coordinating all issues relating to incoming and outgoing Erasmus+ students.
- Director of Studies TBLS (Truman Bodden Law School, Cayman Islands) (2014-2016), having within my remit managing the law programmes, taking decisions on a variety of matters, from suspensions, organising programme changes, Chair of the Board of Examiners, Chair of the Board of Studies etc.;
- Member Departmental REF 2014 Committee (2010-2014), having within my remit reading and grading academic publications and preparing for REF2014 submission;
- Deputy Director Laureate on-line learning (2010-2014), having within my remit quality overview of teaching delivery and assessment, co-chairing Board of Examiners and Board of Studies, admission of students for LLM programmes, strategic overview of module and programme development and approval;

1996 - 2003 Maastricht

- Member Executive Board Private Law Department (1999-2003), having within its remit all daily and strategic management of a 40-45 academic staff law department within the Law Faculty. One particular and difficult project was the reorganisation of the department after the Law Faculty went through an economic restructuring process, with fundamental consequences for a number of academic staff. Plans and criteria were drawn up and the process was rolled out.
- Member of the International Affairs Committee (1999-2003), having within its remit the strategic overview and implementation of internationalisation strategies within the Law Faculty.

- **PRIZES**

1998 I won the Goudsmit Prize in the Netherlands for the best scientific article in the field of health law for the article: Octrooirecht en ge(e)n-et(h)ica. Octrooi op menselijke genen en verwante genetische manipulaties, Tijdschrift voor GezondheidsRecht, 1998/4, 186-201 (awarded with the Goudsmit prize for the best scientific publication in the field)

- **MAJOR COLLABORATIONS**

At the University of Copenhagen, I currently work on the following major research project: The Collaborative Research Programme for Biomedical Innovation Law (value 7 million EUR)

The Collaborative Research Programme for Biomedical Innovation Law will focus on innovation inefficiencies on the Life Science Frontiers through 5 concrete interrelated studies complemented by a 6th synergy study.
The common aim of the 5 concrete studies is to optimize legal concepts into enabling tools that will help to bring novel technologies, research and biomedicine together for radical innovation – thereby providing a much-needed contribution to bridging bio-pharmaceutical innovation gaps, enhancing translational medicine and promoting technology transfer. A 6th overarching policy & synergy study will ensure continuous knowledge and synergy across the 5 concrete studies.
The 5 concrete studies and the 6th Synergy study aim to demonstrate how legal science methods, that take careful account of interdisciplinary insights and "real world" perspectives, can both generate and contribute to new knowledge about key factors driving pharmaceutical innovation. In addition, such methods will be utilised to examine how innovation incentives that are not depending on patents can be applied, combined, optimized and conceptualized in order to either substitute or complement patent protection in new areas of crucial medical applications.



This is a major interdisciplinary research project, in collaboration with the University of Cambridge, the University of Harvard (Law School and Medical School) and the University of Michigan, with special advisors at the University of Boston and NYU Law School in New York. A range of senior researchers, senior research fellows, postdoctoral researchers and PhD students work on this project, which has commenced in 2018 and will end in 2024.
Each of the projects within the main Project has a value of about 1 million EUR.

I am one of the key investigators in that project, as the second most senior investigator in this project.

I am co-PI of the project on Orphan Drugs, and I am coordinating the Antibiotics project and the New Uses project. I am moreover an active investigator in Precision Medicine

Other projects I have been involved in as co-author of the tenders and one of the central investigators:

- Effects of Supplementary Protection Mechanisms for Pharmaceutical Products (value 150,000 EUR)
  May 2018, Technopolis Group, 169 pp, downloadable at https://www.rijksoverheid.nl/ministeries/ministerie-van-volksgezondheid-welzijn-en-sport/documenten/rapporten/2018/05/01/effects-of-supplementary-protection-mechanisms-for-pharmaceutical-products
  This study was tendered by the Dutch Ministries of Health and Economic Affairs in 2017, and I was one of lead drafters of the project proposal and one of the lead investigators in that project,

resulting in the report referred to above

- Periodieke beleidsevaluatie Intellectuele Eigendomsbeleid (Evaluation IP policies), Technopolis, May 2018 (value 150,000 EUR)
  This study was tendered by the Dutch Ministry Economic Affairs in 2017, and I was one of lead drafters of the project proposal and one of the lead investigators in that project, resulting in the report referred to https://www.rijksoverheid.nl/documenten/rapporten/2018/05/01/periodieke-beleidsevaluatie-intellectuele-eigendomsbeleid

- Study on a collaboration system for commercialisation of intellectual property in the EU (July 2019, value 150,000 EUR)
  Study tendered by the European Commission, and I was one of lead drafters of the project proposal and one of the lead investigators in that project led by Technopolis Group

- Danish Research Council funding application related to COVID-19: Principal Investigator for a collaborative project relating to pandemic preparedness, access to affordable medical treatments, PPE etc., in the context of the existence of exclusive rights, amongst which IP rights (2020, total value 3 million DKK (405,000 EUR), not successful, success rate was 2%, only 1 legal project was awarded for the entire call, and it related to the track and trace app and privacy issues)

- Nordforsk funding application in the Nordpermed framework (2018, total value 3 million EUR, not successful)
  The project NordIIc-PM (Nordic Infrastructure Innovation in Personalized Medicine) focused on important prerequisites that need to be in place to deliver on the promises of personalized medicine for patients in the Nordic health care systems. NordIIc-PM addressed major hurdles for making personalized medicine a reality and suggests solutions to address and overcome them. It was a multidisciplinary collaboration between the University of Copenhagen, Oslo (and the University hospital in Oslo), Uppsala and Gothenburg University.

  "Major barriers that need to be resolved and currently prevent swift implementation of precision medicine in the Nordic countries are failures related to real or perceived legal obstacles, diverging legal interpretations between stakeholders, lack of innovative data sharing approaches across the Nordics, and collaboration deficits between stakeholders. These stakeholders (health care workers, researchers, industry, legal specialists, data protection officers, data managers and biostatisticians, regulatory authorities, data protection authorities, and administrators) will be our project partners. Topics to be improved before personalized medicine really can occur in the Nordics are:
  - There is an imminent need to re-evaluate and/or align intellectual property (IP) and data sharing policies in practice to facilitate the translation of research into useful innovations.
  - There is a tension between political and practical considerations related to the access and management of big data, while in keeping with local, national and EU directives and regulations, such as GDPR.
  - Patient trust and support in biomedical research in light of personalized medicine, informed consent, data sharing of sensitive data, and public-private partnerships in research and innovation.
  - There is a need for innovative and joint interpretation of law and policy across the Nordics to enable swift data transfer and exploitation for research and development."

- **LIST OF PUBLICATIONS AND CONFERENCE AND SEMINAR INVITATIONS**

List of all publications

Books:

1- PhD: Enabling Biotechnological Inventions in Europe and the United States. *A study of the patentability of proteins and DNA sequences with special emphasis on the disclosure requirement*, Eposcript Series, nr. 4, EPO, München, 2001, +/- 340 pp;

2- Bostyn et.al (eds.)., Moderne biotechnologie en recht, Serie Recht en Praktijk, 85, 2e druk, Kluwer, Deventer, 2001, + 165 pp;

3- Patenting DNA Sequences (Polynucleotides) and Scope of Protection in the European Union: An Evaluation, Luxemburg, European Communities 2004, +146 pp.

Chapters in books:

4- KNAW (ed.), De gevolgen van het octrooieren van humane genen voor het wetenschappelijk onderzoek in Nederland. Advies van de Commissie Genoctrooien, KNAW, Amsterdam, 2003, 90 pp;

5- 'The unbearable heaviness of harmonization: SPLT and CP', p. 105-153, in M. Ricolfi (ed.), *I brevetti per invenzione fra diritto europeo e diritto nazionale, Scritti di diritto industriale*, Milano: Giuffrè 2004, +160 pp.;

6- IE Recht & Commentaar, Ch. Gielen, D.W.F. Verkade (red), Kluwer, 2005, artt. 2a, 3, 25, 53a, 53b, 53c Rijksoctrooiwet 1995;

7- IE Recht & Commentaar, Ch. Gielen, D.W.F. Verkade (red), Kluwer, 2009, artt. 2a, 3, 25, 53a, 53b, 53c Rijksoctrooiwet 1995;

8- A decade after the birth of the biotech directive: Was it worth the trouble?, in, Emanuela Arezzo, Gustavo Ghidini (eds.), Biotechnology and Software Patent Law: A Comparative Review on New Developments, Edward Elgar Publishing, 2011, p. 221-259;

9- IE Recht & Commentaar, Ch. Gielen, D.W.F. Verkade (red), Kluwer, 2013, artt. 2a, 3, 25, 53a, 53b, 53c Rijksoctrooiwet 1995;

10- The unbearable complications of patenting plants, in, TALLACCHINI MARIACHIARA; LEONINI FERNANDO; Ferrari Matteo (eds.), Innovating Food, Innovating the Law. An interdisciplinary approach to the challenges in the agro-food sector, Tricase, Libellula Edizioni, 2014, 296-330;

11- Patenting personalised medicine and human rights, in, P. Torremans (ed.), Intellectual Property and Human Rights, Kluwer Law International, 2015, 725-782;

12- IE Recht & Commentaar, P.G.F.A. Geerts, D.J.G. Visser (red), Kluwer, 2016, artt. 2a, 3, 25, 53a, 53b, 53c Rijksoctrooiwet 1995;

13- IE Recht & Commentaar, P.G.F.A. Geerts, D.J.G. Visser (red), Kluwer, 2017, artt. 2a, 3, 25, 53a, 53b, 53c Rijksoctrooiwet 1995;

14- IE Recht & Commentaar, P.G.F.A. Geerts, D.J.G. Visser (red), Kluwer, 2019, artt. 2a, 3, 25, 53a, 53b, 53c Rijksoctrooiwet 1995;

15- IE Recht & Commentaar, P.G.F.A. Geerts, D.J.G. Visser (red), Kluwer, 2020, artt. 2a, 3, 25, 53a, 53b, 53c Rijksoctrooiwet 1995 (on-line edition);

16- IE Recht & Commentaar, P.G.F.A. Geerts, D.J.G. Visser (red), Kluwer, 2021, artt. 2a, 3, 25, 53a, 53b, 53c Rijksoctrooiwet 1995;

17- Personalized Medicine, Intellectual Property Rights and Human Rights, in, P. Torremans (ed.), Intellectual Property and Human Rights, Kluwer Law International, 2020, 907-986.

Journal Articles:

18- "Towards a cloned world? Patents in biotechnology." Paper drafted for a conference at Stockholm University at the Institute for intellectual property law and competition law IFIM (Insitutet för Immaterialrätt och Marknadsrätt) on 07/04/1995, 25 pp;

19- Octrooi op dieren; beestachtig?, Nederlands JuristenBlad, 1997/9, 373-377;

20- Octrooieren van klonen en andere biologische merkwaardigheden, De EU ontwerprichtlijn biotechnologische uitvindingen, Bijblad Industriële Eigendom (BIE), 1997, 403-408;

21- Octrooirecht en ge(e)n-et(h)ica. Octrooi op menselijke genen en verwante genetische manipulaties, Tijdschrift voor GezondheidsRecht, 1998/4, 186-201 ***(awarded with the Goudsmit prize for the best scientific publication in the field);***

22- Legal protection of biological elements/La protection juridique des éléments biologiques. Report for the XVth International Congress of Comparative Law 1998, published in, HONDIUS, E. (ed.), Netherlands reports for the XVth International Congress of Comparative Law Bristol 1998, Intersentia, Brussel, 1998, p. 285-316;

23- Review Essay: VAN OVERWALLE, G., Octrooirecht, ethiek en biotechnologie, Brussel, Bruylant, 1998, 183 pp., BIE, 1998, 161-164;

24- The Patentability of Genetic Information Carriers, The new E.U. Directive 98/44 on the legal protection of biotechnological inventions, Intellectual Property Quarterly, 1999/1, 1-36;

25- Kritiek van de onbegrijpelijke redenering. De Novartis zaak voor het EOB, Intellectuele Eigendom en Reclamerecht (IER), 1999, 65-71;

26- The New E.U. Directive 98/44 on the Legal Protection of Biotechnological Inventions; a schematic overview, in, Proceedings of the 4th Euregional Meeting of the Working Group Biotechnology, Aachen, 1999, 26-30;

27- Buchbesprechung: VAN OVERWALLE, G., Octrooieerbaarheid van plantenbiotechnologische uitvindingen. Een rechtsvergelijkend onderzoek naar een rechtvaardiging van een uitbreiding van het octrooirecht tot planten, Brussel, Bruylant, 1996, 747 pp., GRUR Int., 1999, 903-905;

28- Kloontje, kloontje in de mand, wie is de mooiste van het land? De implementatie van de EU richtlijn 98/44 octrooieerbaarheid biotechnologische uitvindingen in Nederland, Tijdschrift voor Gezondheidsrecht, 1999/8, 500-512;

29- Witte rook boven het Europees Octrooibureau. De beslissing van de Grote Kamer van Beroep in de Novartis zaak en de octrooieerbaarheid van planten, BIE, 2000, 201-207;

30- One Patent a Day keeps the Doctor Away? Patenting Human Genetic Information and Health Care, 7 European Journal of Health Law, 2000/3, 229-264;

31- Ik denk, dus ik krijg een octrooi. Octrooieerbaarheid van bedrijfsvoeringsmethodes en ideeën in Europa en de Verenigde Staten, BIE, 2001, 77-88;

32- Het sprookje is uit. De beslissing van het Europees Hof van Justitie inzake de Nederlandse vordering tegen richtlijn 98/44/EG , BIE, 2001, 392-399;

33- DNA-octrooien; mag het ook een beetje meer zijn?, NJB, 2002, 253-259;

34- Tokkyo Seido no Kokusaiteki Chowa, 47 AIPPI Japan Journal, 2002, 20-48;

35- International Harmonization of the Patent System (Part I), 27 AIPPI Journal Japan, 2002, 310-323;

36- International Harmonization of the Patent System (Part II), 27 AIPPI Journal Japan, 2002, 384-397;

37- International Harmonization of the Patent System (Part III), 28 AIPPI Journal Japan, 2003, 29-37;

38- Book review: Warren-Jones, A.; Patenting rDNA. Human and Animal Biotechnology in the United Kingdom and Europe, Lawtext Publishing, Oxon, 2001, 275 pp., 33 IIC, 2002, 996-1000;

39- A European Perspective on the Ideal Scope of Protection and the Disclosure Requirement for Biotechnological Inventions in a Harmonised Patent System; The Quest for the Holy Grail?, 5 Journal of World Intellectual Property, 2002, 1013-1046;

40- A Test too Far? A Critical Analysis of the (Non)-Patentability of Diagnostic Methods and Consequences for BRCA1 Gene Type Patents in Europe, 5 Bio-Science Law Review, [2001/2002] 4, 111-121;

41- The Prodigal Son: The Relationship Between Patent Law and Health Care, 11 Medical Law Review, 2003, 67-120;

42- Written Description after Enzo Biochem: Can The Real Requirement Step Forward Please?, JPTOS, 2003, 131-152;

43- Living in an (Imm)Material World: Bioinformatics and Intellectual Property Protection (Part I), 1 Journal of International Biotechnology Law, 2004, 7-15.

44- Living in an (Imm)Material World: Bioinformatics and Intellectual Property Protection (Part II), 1 Journal of International Biotechnology Law, 2004, 54-61;

45- Biotech Patents and the Future of Scientific Research, in, Proceedings of the General Assembly Conference ALLEA, 2005, 29-47;

46- DNA patents in Europe: Controversy remains, pp. 22-49, in, The Ethics of Patenting Human Genes and Stem Cells, Danish Council of Ethics, Copenhagen, 2005;

47- No Cure Without Pay? Referral to the Enlarged Board of Appeal concerning the patentability of diagnostic methods, EIPR, 2005, 412-419;

48- Narrow trousers and narrow patents, a health risk? Product protection or purpose-bound protection for biotechnological inventions, Bio-Science Law Review, 2004/2005, 89-95;

49- No contact with the human body, please! Patentability of diagnostic methods inventions after G 1/04, [2007] EIPR, issue 6, 238-244;

50- Book review essay, 'Llewelyn, M., Adcock, M., European Plant Intellectual Property, Hart Publishing, Oxford – Portland, Oregon, 2006, xxvi + 551 pp., 44 Common Market Law Review 2007, 1558-1560;

51- Do you wish biological or essentially biological vegetables? (Non-)Patentability of essentially biological processes for the production of plants, BioScience Law review, 2006/2007, 146-155;

52- Van planten-DNA, soyameel, uitputtingsleer en beschermingsomvang: een commentaar op Rb. 's Gravenhage, Monsanto v Cefetra, Argentinië, Vopak en ACTI, BIE, 2008, 342-346;

53- Patenting human embryonic stem cells in peril: the decision of the Enlarged Board of Appeal in G 2/06, BioScience Law Review, vol. 10, 2009, 13-24;

54- How biological is essentially biological? The referrals to the Enlarged Board of Appeal G 2/07 and G 1/08, [2009] EIPR, 549-558;

55- Patenting antibodies after HGS v Lilly: More questions raised than answered, CIPA Journal, October 2012, 573-580;

56- Resolving the patentability of plants produced by an essentially biological process conundrum: Squaring the circle? EIPR 2013, 35(7), 383-396;

57- Patentability of plants: at the crossroads between monopolising nature and protection technological innovation? The Journal of World Intellectual Property (2013) Vol. 16, no. 3–4, pp. 105–149;

58- Bostyn, Sven and Petit, Nicolas, Patent=Monopoly: A Legal Fiction (December 31, 2013). Available at SSRN: http://ssrn.com/abstract=2373471 or http://dx.doi.org/10.2139/ssrn.2373471, 19 pp;

59- Amicus curiae brief in G 2/13 case (46 pp);

60- Personalised medicine, medical indication patents and patent infringement: emergency treatment required, IPQ, 2016, 151-201;

61- Medical treatment methods, medical indication claims and patentability: A quest into the rationale of the exclusion and patentability in the context of the future of personalised medicine, IPQ, 2016, 203-230;

62- Bostyn, S.J.R., Minssen T., A Ray of Light in Muddy Waters? -The CJEU rules on combination SPCs in C-121/17 Teva v Gilead, European Pharmaceutical Law Review, Vol. 2, No. 3, 2018, p. 169-173;

63- Plant Variety Right Protection and Essentially Derived Varieties: A Fresh Proposal to Untie the Gordian Knot, GRUR International, 2020, 785–802;

64- Access to Therapeutics and Vaccines in Times of Health Pandemics: How Exclusivity Rights Can Affect Such Access and What We Can Do About It, IPQ, 2020, 227-270;

65- Incentivising innovation in life sciences from the 1970s to the present: how complex exclusivity strategies became the standard and what it means for us, in, Studi per Vincenzo di Cataldo, G. Giappichelli Editore S.r.l., 2021 (23,000 words);

66- Bostyn, Sven, Why a COVID IP Waiver Is not a Good Strategy (May 10, 2021). Available at SSRN: https://ssrn.com/abstract=3843327 or http://dx.doi.org/10.2139/ssrn.3843327

67- Sinha, Michael and Bostyn, Sven and Minssen, Timo, Addressing Exclusivity Issues During the COVID-19 Pandemic and Beyond (June 7, 2021). Forthcoming, I. Glenn Cohen, Abbe Gluck, Katherine Kraschel, & Carmel Shachar, COVID-19 and the Law: Disruption, Impact and Legacy. Cambridge University Press, 2022, Available at SSRN: https://ssrn.com/abstract=3889894 or http://dx.doi.org/10.2139/ssrn.3889894

68- Bostyn, Sven J.R. 2021. "Towards a Fair Scope of Protection for Plant Breeders' Rights in an Era of New Breeding Techniques: Proposals for a Modernization of the Essentially Derived Variety Concept" *Agronomy* 11, no. 8: 1511. https://doi.org/10.3390/agronomy11081511

69- Bostyn, Sven J.R., Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives, https://blog.petrieflom.law.harvard.edu/2021/09/15/orphan-drug-innovation-incentives/

Reports

70- Bostyn, S.J.R. et al., Final Report of the Expert Group on the development and implications of patent law in the field of biotechnology and genetic engineering, European Commission, (E02973), 2016. 265 pp. (http://ec.europa.eu/growth/industry/intellectual-property/patents/biotechnological-inventions/index_en.htm)

71- Bostyn, S.J.R., Jongh, T. de, Poort, J. Radauer, A., Effects of Supplementary Protection Mechanisms for Pharmaceutical Products, May 2018, Technopolis Group, 169 pp, downloadable at https://www.rijksoverheid.nl/ministeries/ministerie-van-volksgezondheid-

welzijn-en-sport/documenten/rapporten/2018/05/01/effects-of-supplementary-protection-mechanisms-for-pharmaceutical-products

72- Sven Bostyn, Andreas Ligtvoet, Stijn Zegel, Veerle Bastiaanssen, Maarten Koopmans, Anneloes de Ruiter, Geert van der Veen, Periodieke beleidsevaluatie Intellectuele Eigendomsbeleid, May 2018, Technopolis Group, 121 pp, downloadable at https://www.rijksoverheid.nl/documenten/rapporten/2018/05/01/periodieke-beleidsevaluatie-intellectuele-eigendomsbeleid

73- Bostyn, S.J.R., Alfred Radauer, Tobias Dudenbostel, Georg Buchtela, Rainer Pätzold, Lars Langenberg, Study on a collaboration system for commercialisation of intellectual property in the EU, 29 July 2019, 101 pp.

Other

74- De Clercq, Brants & Partners Newsletter, Vol. 1, January 2004, 6 pp;

75- De Clercq, Brants & Partners Newsletter, Vol. 2, April 2004, 6 pp;

76- De Clercq, Brants & Partners Newsletter, Special Edition Bio 2004, 12 pp;

77- Paper drafted for EIPIN Conference London, 7 May 2004, 9 pp.

78- De Clercq, Brants & Partners Newsletter, Vol. 3, January 2005, 10 pp.

79- Employee Inventions in Europe, Paper for Fordham IP Conference 2005, New York, 40 pp.;

80- Employee Inventions in Europe, Paper for IPBA 15th Annual Meeting & Conference on 3-7 May 2005 in Bali, Indonesia, 47 pp.

81- De Clercq, Brants & Partners Newsletter, Vol. 4, September 2005, 10 pp.

82- De Clercq, Brants & Partners Newsletter, Special edition BIO 2006 Chicago, March 2006, 20 pp.

83- De Clercq, Brants & Partners Newsletter, September 2006, 20 pp.

84- De Clercq, Brants & Partners Newsletter, Special edition EPC 2000, October 2007, 20 pp.;

85- De Clercq, Brants & Partners Newsletter, January 2009, 25 pp.

Conference and seminar invitations

All the contributions listed below were on an invitation basis:

1998

1. De nieuwe EU richtlijn biotechnologische uitvindingen. Einde van een tijdperk, of begin van een nieuw tijdperk?", Conferentie vereniging voor industriële eigendom Nederland, 23 September 1998

2000

2. The Information Society and IPRs. What to do? Van Miert Symposium, Maastricht University, 22 May 2000

2001

3. Computer Patent Protection in Europe, EIPA Conference, Amsterdam, 13 June 2001
4. Patent Scope, Disclosure and Biotechnology: Europe and the United States, Intellectual Property Law Conference, Maastricht University, 3 July 2001

2002

5. International Harmonization of the Patent System, International AIPPI Conference, Tokyo, 7 February 2002
6. Biodiversity, Genetic Resources, Health Care and Patent Law, Seminar at GRIPS, Tokyo, 8 February 2002
7. The Quest for the Holy Grail? Disclosure, Scope of Patents and the Enablement Test, International Conference, EPO, The Hague, 19 February 2002
8. Genes, Patents and Health Care, International Medical Law Conference, Maastricht, 13 August 2002
9. Intellectual Property - Challenges for Biotech Products, NVFW Conference, Lunteren, 10 October 2002
10. Genetisch onderzoek en octrooirecht, KNAW Seminar, KNAW Commissie Genoctrooien, 16 October 2002
11. No Free Beers, No Free Patents: Economics of the Patent System and Patent Scope, ETHZ, NDS Geistiges Eigentum, Zürich, November 25, 2002

2003

12. Genes, Patents and Health Care, Seminar University of Montreal, 11 February 2003
13. Patenting DNA: cloudy conditions, no safe landing guaranteed, Conference Munich, 24 February 2003
14. The Future of DNA Patents, Protection of Biotechnological Inventions Annual Conference, Copenhagen, April 28, 2003
15. Protection of Biotechnological Inventions: Recent Issues, Patent Law Conference, Sint-Martens-Latem, June 13, 2003
16. The Community Patent: Value For Money? Patenting Biotechnological Inventions, München, November 17, 2003
17. The Biotech Patent Saga: To Be Continued? Patenting Biotechnological Inventions, München, November 17, 2003

2004

18. Presentation on Database and other IP protection in connection with genetic information databases GBIF, Madrid, 1-2 March 2004
19. The Unbearable heaviness of harmonization: SPLT and CP, SISPI Conference, Torino, 8 March 2004
20. Implementing Directive 98/44/EC: Some Stumbling Blocks, Seminar New developments in biotech patenting, organized by De Clercq, Brants & Partners (DCB), Sint-Martens-Latem (B), 12 March 2004
21. Disclosure and scope of protection of DNA related inventions, Aspects of Bioethics and IPRs Conference, Cambridge, 20 March 2004
22. Biotech Patents And The Future of Scientific Research, ALLEA General Assembly, First Academic Session: Intellectual Property Rights, Brussel, 25 March 2004
23. Narrow trousers and narrow patents, a health risk? EIPIN Conference, London, 6-8 mei 2004
24. Biodiversiteit, toegang tot medicijnen, globalisering en intellectuele eigendomsrechten, presentatie als expert in het kader van een hoorzitting van de Commissie Globalisering van de Belgische Kamer van Volksvertegenwoordigers, Brussel, 21 June 2004
25. Key Current Aspects of the EU Biotech Directive, Protecting Biotech Inventions IBC Conference, Zürich, 21-23 September 2004
26. Experiences on the Granting of Patents for Gene (Partial) Sequences, The Ethics of Patenting Human Genes and Stem Cells, Conference Danish Council of Ethics, Copenhagen, 28 September 2004
27. Patent protection of plants and plant material in Europe, the US and other countries in the world, WIPO Master in IP, Torino, 29 September 2004
28. Plant variety protection in Europe and the United States, WIPO Master Course in IP, Torino, 29 September 2004
29. Patent protection for human biotech inventions, WIPO Master Course in IP, Torino, 30 September 2004
30. SPLT and global harmonization of substantive patent law rules, WIPO Master Course in IP, Torino, 1 October 2004
31. University inventions, WIPO Master Course in IP, Torino, 1 October 2004
32. Octrooieerbaarheid van biotechnologische uitvindingen, dwanglicenties en gezondheidszorg, presentatie als expert in het kader van een hoorzitting van de Commissie Bedrijfsleven van de Belgische Kamer van Volksvertegenwoordigers in het kader van het wetsontwerp implementatie richtlijn 98/44/EG betreffende de wettelijke bescherming van biotechnologische uitvindingen, Brussel, 23 November 2004
33. Diagnostic methods to the EBA, Seminar Bridging the gap between pharma and regulatory, organized by De Clercq, Brants & Partners (DCB), Sint-Martens-Latem, 26 November 2004
34. Patentability of computer-implemented inventions in Europe and the United States, Gastcollege Universiteit Maastricht, Maastricht 8 December 2004
35. First and second medical indication; patent protection for pharmaceuticals, Gastcollege Universiteit Maastricht, Maastricht, 8 December 2004
36. The Road Towards More (Bio)diversity In Patent Law: Lost Highway? Conference Intellectual Property and Fundamental Human Rights, Torino, 17 December 2004

2005

37. Patentability of Diagnostic Methods in Europe, the US and Japan, IBC Conference, Pharmaceutical Patent Life Cycles, 14 March 2005, London;
38. Compulsory Licensing: Remedy Against Hungry Biotech Patent Holders? Conference Maastricht 19-20 May 2005, Free Trade, Competition and the Enforcement of Intellectual Property Rights in a Global Economy;
39. National security and export control in IP licensing, LESI Annual Meeting, München, 15 June 2005;

40. Expert testimony at, Seminar “Counteract the Counterfeiters! Limiting the risks of counterfeit medicines to public health in Europe by adequate measures and mechanisms” Strasbourg, Council of Europe, 21-23 September 2005;
41. Biotech Patents in Europe After the EC Biotech Directive: A Blessing?, Protecting Biotech Inventions IBC Conference – Brussel, 27-28 September 2005;
42. International Harmonisation of Patent Law, Protecting Biotech Inventions IBC Conference – Brussel, 27-28 September 2005;
43. Patent protection of plants and plant material in Europe, the US and other countries in the world, WIPO Master in IP, Torino, 28 September 2005;
44. Plant variety protection in Europe and the United States, WIPO Master Course in IP, Torino, 28 September 2005;
45. Patent protection for human biotech inventions, WIPO Master Course in IP, Torino, 29 September 2005;
46. SPLT and global harmonization of substantive patent law rules, WIPO Master Course in IP, Torino, 30 September 2005;
47. University inventions, WIPO Master Course in IP, Torino, 30 September 2005;
48. Biotech Patents in Europe: Challenges and Opportunities, CORDIA 2005 - IP Master Class, London, 12 October 2005;
49. IER Symposium: De toekomst van het octrooisysteem, Amsterdam, 1 november 2005;
50. Biotech Patents after the Biotech Directive, DCB Seminar, Sint-Martens-Latem (België), 25 November 2005.

2006

51. Intellectual Property in the 21st Century, University College London, 14 December 2006;
52. Enlarged Board of Appeal case law in respect of diagnostic methods, human embryonic stem cells and essentially biological processes for the production of plants, Sint-Martens-Latem, 10 November 2006;
53. Statutory harmonisation in patent law; Is the SPLT able to lead to effective harmonization? Conference, Torino, 9 October 2006;
54. University inventions, WIPO Master Course in IP, Torino, 6 October 2006;
55. SPLT and global harmonization of substantive patent law rules, WIPO Master Course in IP, Torino, 6 October 2006;
56. Patent protection of plants and plant material in Europe, the US and other countries in the world, WIPO Master in IP, Torino, 5 October 2006;
57. Plant variety protection in Europe and the United States, WIPO Master Course in IP, Torino, 5 October 2006;
58. Patent protection for human biotech inventions, WIPO Master Course in IP, Torino, 5 October 2006;
59. Biotech Patents after the Biotech Directive, Protecting Biotech Inventions, IBC Conference, Brussel, 26-27 September 2006;
60. The Unbearable Pleasures of Non-Harmonisation, ESOF Conference, München, 18 July 2006;
61. Open Source Software en licenties, KVIV Cursus Octrooibeleid, Antwerpen, 22 June 2006;
62. Patenting human genetic inventions: Thou shalt think before thou act, PATENTING BIOTECHNOLOGICAL
63. INVENTIONS; DEBATES AND PERSPECTIVES, Organised in the framework of the Austrian Presidency of the European Union, organized by ERA, Vienna, 29-30 May 2006;
64. Licentieovereenkomsten en IE, KVIV Cursus Octrooibeleid, Antwerpen, 30 March 2006;
65. Biotech Patents after the Biotech Directive, FlandersBio Seminar, Leuven, 22 February 2006

2007

66. 'Biotech Patents', Cambridge University guest lecture, 31 January 2007.
67. 'Te veel en te makkelijk triviale octrooien?', AIPPI Symposium Zeist, 14 March 2007.
68. 'Value generation from knowledge protection in medical technologies', Seminar Knowledge Protection in Life Sciences, FlandersBio, Brussel, 22 June 2007.
69. 'Intellectual Property in the 21st Century', High-Level Seminar on Intellectual Property, Tianijn, China, 10 September 2007.
70. 'The role of IP Offices in stimulating creativity and innovation', High-Level Seminar on Intellectual Property, Tianijn, China, 11 September 2007.
71. 'Genetic Resources and IP protection: A weak legal basis for a good cause', Conference: Traditional
72. Knowlede and Intellectual Property: Looking at the Future, Torino, 8 October 2007.
73. 'DNA patents in Europe: how bound is the purpose?', EPO Seminar, Protecting Biotechnological Inventions, Brussel, 8 November 2007.
74. 'New Referrals to the Enlarged Board of Appeal', Seminar De Clercq Brants & Partners, Sint-Martens-Latem, 9 November 2007.
75. 'The role of patents in innovation: Biotechnology and Computer-implemented Inventions', Conference: Innovation, territorial attraction and protection of intellectual property, Benevento, Italië, 18 December 2007.

2008

76. 'Beslag inzake octrooien', Seminar Klos Morel Vos Schaap, Amsterdam, 21 February 2008i.
77. 'Exclusieve rechten octrooihouder', gastcollege Universiteit Antwerpen, 9 April 2008.
78. 'Issues, traps and opportunities when patenting medical combination products', Seminar Combination Products & Implants: Challenges of Convergence, FlandersBio, Brussel, 24 April 2008.
79. 'All dosages are equal, but some are more equal than others', Seminar De Clercq Brants & Partners, Sint-Martens-Latem, 14 November 2008.
80. 'When does one (not) infringe a plant patent?' Seminar De Clercq Brants & Partners, Sint-Martens-Latem, 14 November 2008.
81. 'The entry into force of the London Agreement on translation of European patents', intern seminar 12 February 2008.
82. 'Octrooieerbare materie', college Opleiding Nederlandse Octrooigemachtigden, Utrecht, 19 May 2008.
83. 'Patent litigation', internal seminar 26 June 2008.
84. 'Patent protection of plants and plant material in Europe, the US and other countries in the world', WIPO Master in IP, Torino, 22 September 2008.
85. 'Plant variety protection in Europe and the United States', WIPO Master Course in IP, Torino, 22 September 2008.
86. 'Patent protection for human biotech inventions', WIPO Master Course in IP, Torino, 23 September 2008.
87. 'University inventions', WIPO Master Course in IP, Torino, 24 September 2008.
88. 'SPLT and global harmonization of substantive patent law rules', WIPO Master Course in IP, Torino, 24 September 2008.

2009

89. 'Exclusieve rechten octrooihouder', gastcollege Universiteit Antwerpen, 18 March 2009.
90. 'The unbearable pleasures of patenting in life sciences', Seminar Biolegis, Brussel, 20 March 2009.
91. 'The unbearable conundrum of patenting software', Seminar Quaeso, Antwerpen, 22 September 2009.

92. ‘Pharmaceutical inquiry of the European Commission: an overview of the results’, De Clercq, Brants & Partners annual Patent Seminar, 27 November 2009.
93. ‘Morality, stem cells and patent law: a poisonous cocktail?’, Tiss. EU Fifth International Workshop, 9-11 December 2009
94. ‘Licentie-overeenkomsten en IE’, gastcollege KVIV cursus octrooibeleid, Antwerpen, 26 March 2009.
95. ‘Open Source Software en licenties’, gastcollege KVIV cursus octrooibeleid, Antwerpen, 25 June 2009.
96. ‘Octrooieerbare materie’, college Opleiding Nederlandse Octrooigemachtigden, Utrecht, 18 May 2009.
97. ‘Patent protection of plants and plant material in Europe, the US and other countries in the world’, WIPO Master in IP, Torino, 28 September 2009.
98. ‘Plant variety protection in Europe and the United States’, WIPO Master Course in IP, Torino, 28 September 2009.
99. ‘Patent protection for human biotech inventions’, WIPO Master Course in IP, Torino, 29 September 2009.
100. ‘University inventions’, WIPO Master Course in IP, Torino, 30 September 2009.
101. ‘SPLT and global harmonization of substantive patent law rules’, WIPO Master Course in IP, Torino, 30 September 2009.
102. IP for plants: biological or not, that is the question, Conference WIPO, Genève, 1 Oktober 2009.

2010

103. ‘Exclusieve rechten octrooihouder’, gastcollege Universiteit Antwerpen, 18 March 2010.
104. ‘Octrooieerbare materie’, college Opleiding Nederlandse Octrooigemachtigden, Utrecht, 17 May 2010.
105. ‘Patent protection for human biotech inventions’, WIPO Master Course in IP, Torino, 4 October 2010.
106. ‘Patent protection of plants and plant material in Europe, the US and other countries in the world’, WIPO Master in IP, Torino, 5 October 2010.
107. ‘Plant variety protection in Europe and the United States’, WIPO Master Course in IP, Torino, 5 October 2010.
108. ‘University inventions’, WIPO Master Course in IP, Torino, 6 October 2010.
109. ‘SPLT and global harmonization of substantive patent law rules’, WIPO Master Course in IP, Torino, 6 October 2010.

2011

110. The unbearable complications of patenting agro food products, Innovating Food, Innovating the Law, Conference, Universita Cattolica del Sacro Cuore, Piacenza, 14-15 October 2011
111. The Future of Product Claims in Europe, Annual Patent Law Seminar, De Clercq & Partners, Sint-Martens-Latem, 18 November 2011

2012

112. Is there a future for absolute product patent protection? SCRIPT Seminar, University of Edinburgh, 9 March 2012
113. Recent developments in biotech patenting, University of Liège, 27 March 2012
114. BAAS Annual Conference 2012, 57th Annual Conference (British Association for American Studies), Copyright in the digital age: a dinosaur in the 21st Century? University of Manchester, 12 April 2012
115. Health claims and intellectual property rights: the haves and the have-nots, 4th Summer Academy on Global Food Law & Policy, 23-27 July 2012, Villa La Collina, Cadenabbia – Lake Como, Italy

2013

116. Innovation policy, technology transfer and public private partnerships, guest lecture, University of Maastricht, 26 April 2013
117. Recent developments in biotech patenting, University of Liège, 14 May 2013

2014

118. Intervenant au colloque : Breveter les gènes ? Les défis de la politique européenne", Haut Conseil des biotechnologies, Paris, le 29 avril 2014
119. Lecture, CEIPI IP Summer School, EPO's proceedings 2/3: EPC regulations and EPO's approach on patentability: exclusions of patentability – approach for software and pharmaceutical products – assessment of novelty (disclaimer) and of inventive step (problem-solution approach), Strasbourg, 4 July 2014

2015

120. Recent developments in biotech patenting, University of Liège, 30 April 2015
121. Healthcare Innovation: Regulation and Society", University of Sheffield, 29 June 2015
122. Lecture, CEIPI IP Summer School, EPO's approach on patentability: exclusions of patentability – approach for software and pharmaceutical products – assessment of novelty (disclaimer) and of inventive step (problem-solution approach), 3 July 2015
123. Second medical indication patents and enforcement issues, Annual Patent Law Seminar, De Clercq & Partners, Sint-Martens-Latem, 27 November 2015
124. Patent protection for plants and plant variety protection for plant varieties, conference organised by CIOPORA, 3 December 2015, Venlo
125. The (lack of) inventive step in software and biotech inventions, Symposium University of Amsterdam, Institute for Information Law, 19 December 2015

2016

126. Recent developments in biotech patenting, University of Liège, 23 March 2016
127. The future of biotechnological patents, Brussels, organised by Dutch EU presidency, 18 May 2016
128. Patents and diagnostic testing: another marriage on the rocks or a(n) (un)wanted relationship?, Patents and licenses on biomarkers; a blessing or a burden? EHA/ASH JOINT SYMPOSIUM, Copenhagen, 11 June 2016
129. Lecture, CEIPI IP Summer School, EPO's approach on patentability: exclusions of patentability – approach for software and pharmaceutical products – assessment of novelty (disclaimer) and of inventive step (problem-solution approach), 4 July 2016
130. Van patent tot patient [from patent to patient], debate evening organised by SPUI25 In Spe, 31 October 2016, Amsterdam
131. Pharma and Biotech IP Summit; Transforming tactics into optimal strategies, 3 November 2016, Munich
132. IP Life Sciences Exchange, Maximising innovation, growth and the value of your pharmaceutical and biotechnology IP through practical strategies, 15-16 November, 2016 | Hilton Munich Aiport, Germany
133. Findings of the Expert Group on the development and implications of patent law in the field of biotechnology and genetic engineering, Annual Patent Law Seminar, De Clercq & Partners, Sint-Martens-Latem, 30 November 2016
134. Life Sciences Patents Network Europe, 7 December 2016, London

2017

135. Big Pharma; facts and fabels, debate organised by Uaem (Universities Allied for Essential Medicines), Amsterdam, 23 March 2017;
136. 9th Pharma & Biotech Patent Litigation Conference, Amsterdam, 25-26 April 2017;
137. Life Sciences IP Minds 2017, London, 20-21 June 2017;
138. Lecture, CEIPI IP Summer School, EPO's approach on patentability: exclusions of patentability – approach for software and pharmaceutical products – assessment of novelty (disclaimer) and of inventive step (problem-solution approach), 3 July 2017;
139. "Second medical indication patents and infringement", European Pharma Law Academy 2017, Cambridge 11-13 September 2017;
140. The role of the CJEU in patent law, CEIPI European Patent Litigation Course, 18 November 2017;
141. Plausibility in patent law, Annual Patent Law Seminar, De Clercq & Partners, Sint-Martens-Latem, 1 December 2017;
142. Second medical indication patents: issues and problems, Life Sciences Patents Network Europe, 6 December 2017, London;
143. Issues around SPC protection in Europe, Life Sciences Patents Network Europe, 6 December 2017, London.

2018

144. "Recent developments in biotechnology and plant breeders' rights: Is the system still fit for purpose?", CIOPORA PUBLIC CONFERENCE, "Technical and legal aspects of biotechnology in ornamentals and fruits", THURSDAY, APRIL 26, 2018, ILVO PLANT, MELLE, Belgium;
145. Incentivising drug development in an era of personalized medicine. What has gone wrong and is there anything that we can do about it?, talk given at "CeBIL seminar on Legal Aspects of Medical AI and Precision Medicine", Copenhagen, 21 June 2018;
146. Lecture, CEIPI IP Summer School, EPO's approach on patentability: exclusions of patentability – approach for software and pharmaceutical products – assessment of novelty (disclaimer) and of inventive step (problem-solution approach), Strasbourg, 9 July 2018;
147. "The growing use of trade secrets in medical diagnosis: a desirable development for society?" Talk given at, "Trade Secrets and Innovation - New Paradigms/New Challenges", Copenhagen, 4 September 2018;
148. CeBIL Seminar "Legal Issues Arising from AI and Big Data in the Health and Life Sciences", Copenhagen, 8 October 2018;
149. "Plausibility in life science patents", talk given at University of Basel Conference "Genome Editing - CRISPR als Herausforderung für das Life Sciences-Recht", Basel, 11-12 October 2018;
150. External ad-hoc member of the Meeting of the European Commission Expert Group on Industrial Policy in the presence of outside experts to discuss the application of the Biotech Directive in the field of plants, Brussels, 5 November 2018;
151. "The role of the CJEU in patent law", talk given at the "CEIPI Diploma on Patent Litigation in Europe" course, CEIPI, Strasbourg, 10 November 2018;
152. "Regulatory Complexity: Consistency of the Overall Regulatory Framework", talk given at Max Planck Institute for Innovation and Competition' conference on "Invention and Innovation Incentives in the Life Sciences Market", Berlin, 15-17 November 2018;
153. "Plausibility in life sciences patents", talk given at the "Life Science IP 2018 Conference", London, 27-28 November 2018;

154. “Patentability of antibodies”, talk given at the “Life Science IP 2018 Conference”, London, 27-28 November 2018;
155. “Effects of Brexit on Danish business”, talk given at “BREXIT - a disaster for Danish life science corporations?”, Copenhagen, 10 December 2018;

2019

156. Open Source Software and patenting: a difficult relationship; seminar given at the Flemish Insititute for Biotechnology, Zwijnaarde (Gent), 7 January 2019;
157. The growing use of trade secrets in medical diagnosis and software: a desirable development for society? Seminar om brug af hemmeligholdelse i kommercialiserings-sammenhæng Danske Universiteter (DNNT), 22. januar 2019;
158. The growing use of trade secrets: a desirable development? Innovation & IP Forum and awards, Paris, 30 January 2019;
159. Trade Secrets and Life Sciences, Analyzing the influence of the Trade Secrets Directive (UE Directive 2016/43) on Future Patent Strategies, C5’s 11th Annual Forum on PHARMA BIOTECH PATENT LITIGATION, Amsterdam, 26-27 February 2019;
160. Pharma patent and regulatory Incentives: a critical overview, 15th Legal Conference Medicines for Europe, Amsterdam, 26-27 March 2019;
161. Regulatory Incentives in Pharma and Biotech: A Critical Review, Changing Regulation of Pharmaceuticals: Issues in Pricing, Intellectual Property, Trade and Ethics, University of the Pacific McGeorge School of Law, Sacramento, 5-6 April 2019;
162. Lecture, CEIPI IP Summer School, EPO’s approach on patentability: exclusions of patentability – approach for software and pharmaceutical products – assessment of novelty (disclaimer) and of inventive step (problem-solution approach), Strasbourg, 8 July 2019;
163. Antibiotics and antibodies: Another layer of complexity, Annual CeBil International Symposium (antimicrobial resistance theme), University of Cambridge, 6 September 2019;
164. Second medical use claims and patent infringement after the UK Supreme Court decision in the Pregabalin case, LIFE SCIENCES IP Summit, Munich, 15-16 October 2019;
165. Plant Breeding and the EDV Concept: Challenges of the Past, Opportunities for the Future?, Seminar on the impact of policy on essentially derived varieties (EDVs) on breeding strategy, UPOV, Geneva, Switzerland, 30 October 2019;
166. IP and Regulatory challenges relating to gene editing of plants, ALLEA-KVAB Symposium Genome Editing for Crop Improvement, Brussels, 7-8 November 2019;
167. Intellectual property and the future of healthcare in a world of AI, robotics and intelligent medical devices: a blessing or a curse?, NEW TECHNOLOGIES IN HEALTH: MEDICAL, LEGAL AND ETHICAL ISSUES, Thessaloniki, 21-22 November 2019;
168. Patent Infringement and Second Medical Use Claims: A Problem That Is Not a Problem?, Life Science IP, London, 26-27 November 2019:
169. “The role of the CJEU in patent law”, talk given at the “CEIPI Diploma on Patent Litigation in Europe” course, CEIPI, Strasbourg, 14 December 2019.

2020

170. ‘Patent protection for human biotech and pharma inventions’, WIPO Master Course in IP, Torino, 19 February 2020;
171. ‘Patent protection of plants and plant material’, WIPO Master in IP, Torino, 20 February 2020;
172. Pharma patents and regulatory Incentives: a critical overview, 16th Legal Conference Medicines for Europe, London, 1-2 April 2020 (postponed to 2021 due to COVID-19);

173. Patenting biotech inventions, speech given at the Dutch government Committee for Genetic Modification, Utrecht, 15 May 2020 (cancelled due to COVID-19);
174. Lecture, CEIPI IP Summer School, EPO's approach on patentability: exclusions of patentability – approach for software and pharmaceutical products – assessment of novelty (disclaimer) and of inventive step (problem-solution approach), Strasbourg, 6 July 2020 (cancelled due to COVID-19).
175. Essentially Derived Varieties: A Balanced Solution, CIOPORA Online PVP Forum, 15 October 2020 (on-line);
176. Abilify Mycite (smart pill drug medical device combination), IP management aspects & related strategic dimensions, WIPO IP Management: A Product-Based Analysis Workshop, 15 October 2020 (on-line)
177. "The role of the CJEU in patent law", talk given at the "CEIPI Diploma on Patent Litigation in Europe" course, CEIPI, Strasbourg, 12 December 2020 (on-line).

2021

178. COVID-19, access to medical treatments and technological and transactional opacity, LAW, TECHNOLOGY & DISRUPTION CONFERENCE, 19-21 March 2021, City University Hong Kong (on-line);
179. Pharma patents, Master's Degree Program in Intellectual Property Law, Tongji University (Shanghai) and WIPO, 9 April 2021 (on-line);
180. Data and market exclusivity for authorised medicinal products, Master's Degree Program in Intellectual Property Law, Tongji University (Shanghai) and WIPO, 13 April 2021 (on-line);
181. COVID-19, IP rights and access, Master's Degree Program in Intellectual Property Law, Tongji University (Shanghai) and WIPO, 14 April 2021 (on-line);
182. 'Patent protection for human biotech and pharma inventions', WIPO Master Course in IP, Torino, 5 May 2021 (on-line);
183. 'Patent protection of plants and plant material', WIPO Master in IP, Torino, 6 May 2021 (on-line);
184. "Patents for New Breeding Techniques: Obtaining Patents", CIOPORA Academy, 9 September 2021;
185. "Patents for New Breeding Techniques: Enforcement and Freedom to operate", CIOPORA Academy, 16 September 2021;
186. Orphan Drug Innovation Needs and Priorities: CeBIL Symposium 2021, Cambrigde University, 17 September 2021;
187. "Landmark Case Law of the EPO in Plant Related Inventions", CIOPORA Academy, 30 September 2021;
188. "The role of the CJEU in patent law", talk given at the "CEIPI Diploma on Patent Litigation in Europe" course, CEIPI, Strasbourg, 20 November 2021 (on-line);